The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Clinical outcomes of patients with CLL receiving long-term ibrutinib in the RESONATE-2 study
Thomas J Kipps, MD, PhD, UC San Diego, Moores Cancer Center, La Jolla, CA, shares some long-term results from the RESONATE-2 study (NCT01724346), which evaluated the efficacy of ibrutinib versus chlorambucil in patients with chronic lymphocytic leukemia (CLL). Dr Kipps first discusses the selection criteria for patients in this trial, and then goes on to share the results, which demonstrated a progression-free survival (PFS) of 87% in patients receiving ibrutinib, and the higher efficacy of ibrutinib versus chlorambucil. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
